Clinical application of cardiovascular pharmacogenetics (Q26849254)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742397%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Clinical application of cardiovascular pharmacogenetics (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742397%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742397%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Geoffrey S Ginsburg

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742397%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

1 reference

1 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742397%20AND%20SRC:MED&resulttype=core&format=json

Journal of the American College of Cardiology

6 February 2020

published in

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742397%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

60

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742397%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742397%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

9-20

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742397%20AND%20SRC:MED&resulttype=core&format=json

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Pharmacogenetic study of statin therapy and cholesterol reduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Sex differences in platelet reactivity and response to low-dose aspirin therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Digoxin pharmacokinetics and MDR1 genetic polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Impact of P-glycoprotein on clopidogrel absorption

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

The SLCO1B1*5 genetic variant is associated with statin-induced side effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Clinical and genetic modifiers of long-term survival in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Ca

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidog

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Gly389Arg polymorphism of β1-adrenergic receptor is associated with the cardiovascular response to metoprolol

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

PlA2 polymorphism and efficacy of aspirin

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Identification of the gene for vitamin K epoxide reductase

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

An association study of 43 SNPs in 16 candidate genes with atorvastatin response

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Diuretic–gene interaction and the risk of myocardial infarction and stroke

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Genetic determinants of response to warfarin during initial anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

SLCO1B1 variants and statin-induced myopathy--a genomewide study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Genetic determinants of response to clopidogrel and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Cytochrome p-450 polymorphisms and response to clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Estimation of the warfarin dose with clinical and pharmacogenetic data

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Ethnic Differences in Response to β1Adrenoceptor Blockade by Propranolol

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

SNP selection at the NAT2 locus for an accurate prediction of the acetylation phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Pharmacology and physiology of human adrenergic receptor polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Platelet reactivity is a stable and global phenomenon in aspirin-treated cardiovascular patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Identification of genetic variants associated with response to statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Can we override clopidogrel resistance?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

CYP4F2 genetic variant alters required warfarin dose

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Effect of PlA1/A2 glycoprotein IIIa gene polymorphism on the long-term outcome after successful coronary stenting

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

A combined genome-wide linkage and association approach to find susceptibility loci for platelet function phenotypes in European American and African American families with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Pharmacogenetics of beta-blockers

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.01.067

7 January 2021

10.1016/J.JACC.2012.01.067

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742397%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742397%20AND%20SRC:MED&resulttype=core&format=json